JP6449845B2 - 疼痛の処置のためのナトリウムチャネルモジュレーター - Google Patents
疼痛の処置のためのナトリウムチャネルモジュレーター Download PDFInfo
- Publication number
- JP6449845B2 JP6449845B2 JP2016501972A JP2016501972A JP6449845B2 JP 6449845 B2 JP6449845 B2 JP 6449845B2 JP 2016501972 A JP2016501972 A JP 2016501972A JP 2016501972 A JP2016501972 A JP 2016501972A JP 6449845 B2 JP6449845 B2 JP 6449845B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- pain
- sulfamoyl
- compound
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UHZFGTXFKBGFMX-UHFFFAOYSA-N CC(OCC(O1)=C(C)OC1=O)=O Chemical compound CC(OCC(O1)=C(C)OC1=O)=O UHZFGTXFKBGFMX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787618P | 2013-03-15 | 2013-03-15 | |
| US61/787,618 | 2013-03-15 | ||
| PCT/US2014/025809 WO2014151472A1 (en) | 2013-03-15 | 2014-03-13 | Sodium channel modulators for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512844A JP2016512844A (ja) | 2016-05-09 |
| JP2016512844A5 JP2016512844A5 (enExample) | 2017-09-07 |
| JP6449845B2 true JP6449845B2 (ja) | 2019-01-09 |
Family
ID=51580969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501972A Active JP6449845B2 (ja) | 2013-03-15 | 2014-03-13 | 疼痛の処置のためのナトリウムチャネルモジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10179781B2 (enExample) |
| EP (1) | EP2968234B1 (enExample) |
| JP (1) | JP6449845B2 (enExample) |
| KR (1) | KR20150131254A (enExample) |
| CN (1) | CN105188694B (enExample) |
| AU (1) | AU2014234105B2 (enExample) |
| BR (1) | BR112015022096A8 (enExample) |
| CA (1) | CA2900604A1 (enExample) |
| ES (1) | ES2687481T3 (enExample) |
| HK (1) | HK1219060A1 (enExample) |
| IL (1) | IL242564A0 (enExample) |
| MX (1) | MX363680B (enExample) |
| MY (1) | MY188139A (enExample) |
| PH (1) | PH12015501740A1 (enExample) |
| RU (1) | RU2669367C2 (enExample) |
| WO (1) | WO2014151472A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| KR20140091022A (ko) | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6449845B2 (ja) | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
| SG10201805552PA (en) * | 2013-09-10 | 2018-08-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
| MX2016006936A (es) | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
| EP3193610A4 (en) * | 2014-09-09 | 2018-04-04 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
| CN104710379B (zh) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | 一种bms‑191011的合成方法 |
| JP2018520107A (ja) | 2015-05-22 | 2018-07-26 | ジェネンテック, インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CR20180242A (es) | 2015-09-28 | 2018-08-10 | Genentech Inc | Compuestos terapéuticos y sus métodos de uso |
| MX386261B (es) | 2015-10-07 | 2025-03-18 | Univ Arizona | Inhibidores de sumoilacion de crmp2 y usos de los mismos |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| MX2018007450A (es) | 2015-12-18 | 2018-11-14 | Merck Sharp & Dohme | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje. |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MX388175B (es) | 2016-10-17 | 2025-03-19 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| ES2987852T3 (es) | 2018-09-10 | 2024-11-18 | Kaken Pharma Co Ltd | Novedoso derivado de amida heteroaromática y medicamento que lo contiene |
| US20220125784A1 (en) * | 2019-02-04 | 2022-04-28 | Simon Fraser University | Methods and compounds for inhibition of inactivation of voltage-gated sodium channels |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| US12533341B2 (en) | 2019-12-11 | 2026-01-27 | Duke University | Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| NZ528639A (en) * | 2001-03-14 | 2005-07-29 | Gruenenthal Chemie | Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| RU2006107211A (ru) * | 2003-08-08 | 2007-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| AU2005266090A1 (en) | 2004-07-23 | 2006-02-02 | Pfizer Inc. | Pyridine derivatives |
| WO2006046916A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| SI1966130T1 (sl) | 2005-12-23 | 2014-02-28 | Zeeland Pharma A/S | Modificirane lizin-mimetične spojine |
| WO2009012241A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| EP2435407B1 (en) | 2009-05-29 | 2019-12-25 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| WO2011133729A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| CA2804173C (en) * | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
| ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
| WO2012004714A2 (en) * | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| CA2804877A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| MX2013008282A (es) | 2011-01-18 | 2014-02-10 | Amgen Inc | Ratones con genes inactivados nav1.7 y usos. |
| JP2014521749A (ja) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| EP2758053A1 (en) | 2011-09-21 | 2014-07-30 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
| JP6449845B2 (ja) | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
| CN110372550B (zh) | 2013-09-09 | 2021-08-24 | 佩洛通治疗公司 | 芳基醚及其用途 |
| SG10201805552PA (en) * | 2013-09-10 | 2018-08-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
-
2014
- 2014-03-13 JP JP2016501972A patent/JP6449845B2/ja active Active
- 2014-03-13 US US14/776,016 patent/US10179781B2/en active Active
- 2014-03-13 ES ES14767550.8T patent/ES2687481T3/es active Active
- 2014-03-13 MX MX2015011907A patent/MX363680B/es unknown
- 2014-03-13 RU RU2015133310A patent/RU2669367C2/ru not_active IP Right Cessation
- 2014-03-13 MY MYPI2015702635A patent/MY188139A/en unknown
- 2014-03-13 BR BR112015022096A patent/BR112015022096A8/pt not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/025809 patent/WO2014151472A1/en not_active Ceased
- 2014-03-13 AU AU2014234105A patent/AU2014234105B2/en not_active Ceased
- 2014-03-13 CN CN201480014410.XA patent/CN105188694B/zh not_active Expired - Fee Related
- 2014-03-13 HK HK16107214.7A patent/HK1219060A1/zh unknown
- 2014-03-13 KR KR1020157029193A patent/KR20150131254A/ko not_active Abandoned
- 2014-03-13 EP EP14767550.8A patent/EP2968234B1/en not_active Not-in-force
- 2014-03-13 CA CA2900604A patent/CA2900604A1/en active Pending
-
2015
- 2015-08-07 PH PH12015501740A patent/PH12015501740A1/en unknown
- 2015-11-12 IL IL242564A patent/IL242564A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015133310A (ru) | 2017-04-20 |
| PH12015501740A1 (en) | 2015-10-19 |
| HK1219060A1 (zh) | 2017-03-24 |
| IL242564A0 (en) | 2016-02-29 |
| MY188139A (en) | 2021-11-23 |
| CN105188694A (zh) | 2015-12-23 |
| EP2968234A4 (en) | 2016-10-12 |
| BR112015022096A2 (pt) | 2017-07-18 |
| MX363680B (es) | 2019-03-29 |
| KR20150131254A (ko) | 2015-11-24 |
| MX2015011907A (es) | 2016-05-16 |
| AU2014234105A1 (en) | 2015-09-03 |
| WO2014151472A1 (en) | 2014-09-25 |
| CN105188694B (zh) | 2018-07-31 |
| US20160046617A1 (en) | 2016-02-18 |
| BR112015022096A8 (pt) | 2019-11-26 |
| CA2900604A1 (en) | 2014-09-25 |
| AU2014234105B2 (en) | 2019-01-03 |
| RU2669367C2 (ru) | 2018-10-11 |
| JP2016512844A (ja) | 2016-05-09 |
| EP2968234B1 (en) | 2018-06-27 |
| US10179781B2 (en) | 2019-01-15 |
| RU2015133310A3 (enExample) | 2018-02-28 |
| ES2687481T3 (es) | 2018-10-25 |
| EP2968234A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6449845B2 (ja) | 疼痛の処置のためのナトリウムチャネルモジュレーター | |
| JP6445565B2 (ja) | とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 | |
| JP6351182B2 (ja) | ガンの治療方法 | |
| ES2786298T3 (es) | Inhibidores de benzimidazol del canal de sodio | |
| RU2710928C2 (ru) | Антагонисты рецептора flt3 | |
| US8247401B2 (en) | P2X3 receptor antagonists for treatment of pain | |
| JP5552430B2 (ja) | 疼痛の治療用としてのp2x3受容体アンタゴニスト | |
| JP2012521429A (ja) | 疼痛治療用のp2x3受容体アンタゴニスト | |
| JPWO2014098098A1 (ja) | 複素環アミド誘導体及びそれを含有する医薬 | |
| JP2014514259A (ja) | 疼痛および他の障害の処置のための化合物および方法 | |
| JP2017527573A (ja) | 糖尿病の治療用の選択的NaV1.7阻害剤 | |
| US20220280644A1 (en) | "TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND | |
| HK1224572A1 (en) | Sodium channel modulators for the treatment of pain and diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170707 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6449845 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |